We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.875 | 0.85 | 0.90 | 0.875 | 0.875 | 0.88 | 116,116 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.59 | 2.39M |
Date | Subject | Author | Discuss |
---|---|---|---|
24/5/2018 11:51 | asking 23.4 to buy atm... | purple11 | |
24/5/2018 00:09 | They're not buys. It's a rollover | bernymadoff | |
23/5/2018 14:53 | Was this just walked down for those 2 x 100k buys? | l0ngterm | |
21/5/2018 22:59 | A few more nuggets from last week's meetings which are worth recording for prosperity (whilst I still remember): * For the ongoing STEM study, SF stated that we should not place much emphasis on overall survival (OS) time, as this is not extended significantly using other treatments such as Pfizer's IBRANCE. However, IBRANCE does improve Progression free survival and Clinical Benefit Ratio (CBR), so the efficacy outcome to look out for in Evgen's study is CBR. * Naturally occurring Sulforaphane is the enantiomerically pure (R) isomer, SFX-01 is made with the corresponding racemate (i.e. a 50/50 mix of R and S enantiomers). The calculations to determine the dose used in the two ongoing clinical trials have taken this into account. * The half life of Sulforaphane in plasma is approximately 2.5 hours, but this is not what determines the twice daily dosing schedule in the Breast cancer study (STEM), what is more important is the half life in the effect compartment, which is considerably longer than 2.5 hours. * The main metabolites of Sulforaphane (glutathione, cysteine and N acetyl cysteine conjugates) have biological activities similar to sulforaphane (which is not always the case with metabolites of other drugs) | timbo003 | |
21/5/2018 17:49 | Where's the pr*t ramper cudmore gone | bauchsapt | |
20/5/2018 19:28 | Aeg ready to fly!ireal RNS!!Sorry wrong board! | costax1654x | |
20/5/2018 16:22 | Evgen's stockopedia report and presentation from our London seminar on the 16th May are available in our members area here: | sharesoc | |
18/5/2018 14:49 | Discovered that my SIPP provider now allows EVG to be held. Previously they said the market cap was too small. So topped up :) Interim trial results within six weeks. A reminder of some of the science; "Sensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants" | pdt | |
18/5/2018 10:07 | Looks like the pump is now done. Sellers locking in at the end of the week. | the_merlion | |
18/5/2018 09:01 | took a few of these today and yesterday - don’t usually do biotec but valuation looks really compelling. Stock pretty tight, mm’s were bidding heavy when they dropped it first thing yesterday. | bumpa33 | |
18/5/2018 08:09 | timbo Thats really interesting as i know its been touted a few times , the concerns that SF didnt seem to have a large Holding/investment here .. Maybe because he doesnt have a huge amount of money and good to know he has invested everything he has | chalky230 | |
18/5/2018 07:43 | One snippet worth mentioning from last night. SF said that he had just about everything riding on the success of Evgen and he did not own any other significant investments, he had even sold his house and was now living in rented accommodation in order to help fund the company. | timbo003 | |
18/5/2018 07:23 | Nobby Thats great , Really appreciate your views and feedback thanks All sounds very interesting PDT Good calculation .. we know one for certain from last year and we just need to guess what "others" mean ... i understand we also know there has been no mortality to date I think by interim all patients are likely to be started and im guessing somewhere between 20 -30 finished the 24 weeks Im with Nobby in that you wouldnt think the company would be out on a speaking tour if they didnt think results were going to be met | chalky230 | |
18/5/2018 07:07 | Just bought 20k via Spreadbet! | nobbygnome | |
18/5/2018 06:42 | >> immy Plus of course the drug is taken as a pill twice a day. So the required drug level will be there all the time. This is refreshing after the homeopathic concentration of another drug we could mention.... | nobbygnome | |
18/5/2018 06:37 | The Ibrance class of drugs is forecast to do c$9 billion sales in 2021. Nice market size in one indication for Evgen to follow on from with apparently little or no competition once CDK4/6 treatment fails. I wonder if Franklin is trying to get the story out there before announcing the interims so that the market cap can more fairly reflect the opportunity. Why would someone pay $50 million up front when they can pay say $40 million to buy the company outright? If the market cap is higher then the company can reject a takeover offer at this stage. I would like to see the company remain independent until after both P2 results in 12 months time. | pdt | |
18/5/2018 06:27 | If 20% is the magic number to respond you can do some back of the envelope calculations at December 2017. If there were 18 people in the trial and at least 3 were in the compassionate use trial ie tumour growth arrested or better as a requirement to continue. I use 3 because they said 1 had been using SFX for a year and others had entered compassionate use as well. Therefore, the result is at least 3/18 or 17% as a minimum. I admit still tenuous guesswork but the odds look quite good. | pdt | |
18/5/2018 06:24 | >> immy LOL I asked that specific question last night after he showed that 5uM was required in vitro to kill tumours and he said including active derivatives that was the concentration reached in vivo. Hallelulia!!! >> chalky Remember this is end stage breast cancer patients we are talking about here. A 20% response rate is what the KOLs think is clinically significant. That is at 6 months. There is a good chance the 3 month figure will be higher. As I said these are end stage patients so even 3 months is relevant. As with all drugs sulforaphane would work much better in earlier patients but the nature of the trials is that it is much easier to do them in end stage patients. A group of us had a long discussion with him afterwards and taking everything together I was very impressed. The science is believable and the patent position is very sound as far as I can tell. This is an open label study so he must know the results already and I don't think he would be out on a speaking tour, if these figures weren't going to be met. At £20 million with a positive interim and then final result, the market cap has to be much higher than that. They are positioning the drug as a follow on once Ibrance has failed,which is very sensible. Who makes Ibrance? Pfizer! It would make sense to me for Pfizer to either license the drug or buy Evgen for sulforaphane so that they can offer the physician the whole treatment paradigm for the patient. Nobby | nobbygnome | |
17/5/2018 22:33 | Chalky I think he answered my question, the phase 2 trial for breast cancer is not a sfx-01 vs placebo trial it is a sfx-01 in addition to 3 commonly used treatments for this Illness. I suppose 20 percent would be a good figure to achieve in this area. Will do some digging over the weekend Thanks nobby, we may have our differences on imm but interesting to see you here. At least you like the dosing and moa here don't you ? Haha I figured itd be week 12 data with some, if any, week 24 data, as is usual in most interims. I remain to see the numbers from interims before going long , there some money here in sentiment in the meantime. I dont understand the preclinical science as it is to make a call unfortunately | immy1992 | |
17/5/2018 22:05 | Nobby Good to see you on here , have seen your posts on imm and always informative, if not to everyones liking :) Can i ask why 20 % is so significant , to me with no scientific understanding , it sounds quite low figure ? Can i also ask what impressed you most about the presentation ? | chalky230 | |
17/5/2018 20:52 | Yes that is correct. The magic number is 20% of patients need to respond. That is what you should look out for when the results are reported. The 6 month figures are the most important but 3 months in breast cancer are also relevant. There is a good chance that 3 months will be higher than 6 months for obvious reasons. So the bottom line is a 20% response rate at 6 months means we have a serious drug on our hands! Nobby | nobbygnome | |
17/5/2018 19:43 | These results are interims for the breast cancer trials yes ? From what I see on clinical trial the completion date is in q4? Would be interesting to see what comes of it. Do you or anyone here happen to know the average clinical benefit rate based on the 3 other drugs used at the moment ? Google not being very helpful at the moment. Thanks | immy1992 | |
17/5/2018 19:13 | At the Proactive presentation. He reiterated results in the first half so definitely due before the end of June. Very interesting presentation, although I have a few more questions for him. Nobby | nobbygnome |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions